La tunisie Medicale - 2022 ; Vol 100 ( n°011 ) : 782-787
[ 755 times seen ]
Introduction: The treatment of certain psychotic, behavioural and delusional symptoms in the elderly frequently involves the prescription of antipsychotics. Prescribing such drugs to elderly patients has recently been called into question, leaving physicians with little or nothing to treat a range of symptoms that are often complex and difficult to treat. Aims : The study aimed to evaluate the prescription of antipsychotics amongst elderly and to compare it with data in the literature. Methods : This retrospective cohort study included patients aged 65 and older admitted to the psychiatric ward of Mahdia University Hospital over the period from 2014 to 2018 who received antipsychotic treatment during their hospitalization. Results : The sample consisted of 44 elderly patients, with 31.8% patients using atypical agents, 34.1% using typical agents, 27.3% received both of them and 6.8% received a long-acting injectable antipsychotic. A majority of the elderly study sample were men (75 %). The mean (SD) age of the study sample was 69.8 years. 61.3% had at least somatic comorbidity. The most common diagnosis was schizophrenia with 31.8%, followed by dementia (27.3%). 34.1% reported adverse effects due to antipsychotic treatment. Conclusion : The study findings suggest that there is a need to be cautious when prescribing antipsychotic in the elderly population. Patient education and regular follow-up of patients can be instrumental in minimizing the adverse outcomes associated with the use of antipsychotics in the the aging population.
Key - Words
  1. Sciolla A, Jeste DV. Use of antipsychotics in the elderly. Intern J Psychiatry Clin Pract.1998;2:S27-S34.
  2. Targum SD, Abbott JL. Psychoses in the elderly: a spectrum of disorders. J Clin Psychiatry. 1999;60(8):4-10.
  3. Copeland JR, Dewey ME, Scott A, et al. Schizophrenia and delusional disorder in older age: community prevalence, incidence, comorbidity, and outcome. Schizophr Bull. 1998;24(1):153-161.
  4. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry. 1998;59:5-10.
  5. Artero S, Ancelin ML, Ritchie K. Épidémiologie des maladies mentales dans le grand âge. Encéphale. 2006;32(6):1091-4.
  6. Rigaud AS, Bayle C, Latour F, Lenoir H, Seux ML, Hanon O, et al. Troubles psychiques des personnes âgées. EMC-O, et al. Troubles psychiques des personnes âgées. EMCPsychiatrie. 2005;2(4):259-81.
  7. Benoît M, Camus E, Cnockaert X, Nourashemi F, Pancrazi MP, Plas J et al. La prescription des antipsychotiques chez le sujet âgé. Les cahiers de l’année gérontologique. 2009;1(3):149-63.
  8. Acheche H. Profil épidémiologique des sujets âgés hospitalisés en psychiatrie. A propos de 100 cas. Mémoire de gérontopsychiatrie. Monastir, 2010.
  9. Khammassi N, Mansour AB, Abdelhedi H, Cherif O. Les effets indésirables des psychotropes chez le sujet âgé: étude rétrospective de 35 cas. Annales Médico-psychologiques, revue psychiatrique 2012;170(4):251-55.
  10. Smith B, Hassett A, Harrigan S, Fortune T. A profile of inpatient admissions to an aged psychiatry service in Victoria. Australasian Psychiatry. 2010;18(2):146-51.
  11. Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. Journal of Clinical Psychiatry. 2000;61(14):49-52.
  12. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimetic induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 2002;52:438–45.
  13. Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer’s disease. J Clin Psychiatry 2001;62:34–40.
  14. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord 2002;13:67–73.
  15. Brodaty H, Sachdev P, Rose N, Rylands K, Prenter L. Schizophrenia with onset after age 50 years. Phenomenology and risk factors. Br J Psychiatry 1999;175:410–5.
  16. McDonald WM, Epidemiology. etiology and treatment of geriatric mania. J Clin Psychiatry 2000;61:3–11.
  17. Bruce ML, McAvay GJ, Raue PJ, Brown EL, Meyers BS, Keohane DJ, et al. Major depression in elderly home health care patients. Am J Psychiatry 2002;159:1367–74.
  18. [18] Bastan M, Stefos G. L’utilisation des antipsychotiques chez la personne âgée. Revue médicale de Bruxelles. 2004;25(4):A-308.
  19. Ardiet G, Monnier N, Poli A. Évolution des traitements psychotropes pour les personnes âgées en institution, entre 2004 et 2012, dans le Rhône. InAnnales Médicopsychologiques, revue psychiatrique 2013 May 1 (Vol. 171, No. 4, pp. 257-261). Elsevier Masson.
  20. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. The Journal of clinical psychiatry. 2004;65:5-99.
  21. Legrand G, Tourtauchaux R, Jalenques I. Prescription d’antipsychotiques de deuxième génération chez les patients souffrant de schizophrénie devenus âgés. Annales Médicopsychologiques, revue psychiatrique. 2012;170(4):278-82.
  22. Drunat, O. Psychotropes chez les personnes âgées: les précautions d’emploi poussent à la précision clinique mais certainement pas à l’abstention médicamenteuse!. NPG Neurologie-Psychiatrie-Gériatrie.2012 ;12(67) :1-2.
  23. Charfi N, Omri S, Smaoui N, Feki R, Zouari L, Thabet JB, et al. Le maniement des psychotropes dans les maladies du système nerveux central. L’Encéphale. 2021 Oct 1;47(5):461-9.
  24. Bullock R, Saharan A. Atypical antipsychotics: Experience and use in the elderly. Int J Clin Pract 2002;56:515–25.
  25. Freyche C, Zacarin A, Bagheri H. Prescription de psychotropes potentiellement inappropriés chez les sujets âgés en Occitanie Ouest. Therapies. 2022 Sep 1;77(5):541-8.
  26. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716–9.
  27. Rudolf J, Ghaemi M, Schmulling S. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. Eur Psychiatry 1999;14:356–7.
  28. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561–6.
  29. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine induced elevation of plasma triglyceride levels. Am J Psychiatry 1999;156:1471–2.
  30. Vaugeois JM, Faure S. Médicaments allongeant l’intervalle QT, un risque à ne pas négliger. Actualités Pharmaceutiques. 2022 Mar 1;61(614):53-7.
  31. Kennedy M, Koehl J, Gao J, Ciampa KA, Hayes BD, Camargo CA Jr. Use of antipsychotic and sedative medications in older patients in the emergency department. J Am Geriatr Soc. 2022 Mar;70(3):731-742.
E-mail :
Password :
Remember Me Forgot password? Sign UP
Keywords most used
Tunisia treatment Child diagnosis surgery prognosis epidemiology Children Risk factors prevalence Crohn’s disease Breast cancer obesity Cancer screening
Sign up to receive our newsletter
E-mail :
Stay in Touch
Join Us! !